Kornimate/medical-research-clean huggingface dataset:
fertility desires and reproductive needs of transgender people

Conditions: Fertility Preservation; Parenting; Gender Dysphoria

Summary: majority of transgender and gender nonconforming people seeking medical care are in pubertal and reproductive age. cross-sex hormones may compromise fertility especially when preceded by puberty blocking regimen. our current understanding on reproductive needs of transgender persons is insufficient. the guidelines of endocrine society and the world professional association for transgender health prompt the health professionals to provide information on fertility risk and fertility preservation options before initiating hormonal treatment. currently, no clear tools are available for healthcare professionals. among several challenges for clinical care are a low clinical awareness, a lack of suitable psycho-educational instruments addressing fertility values that can be used to facilitate discussion between transgender persons and healthcare providers, a lack of established methods for fertility preservation in prepubertal youth, and a lack of long-term data regarding reproductive function, psychological and societal outcomes in this population. likewise, current data are sparse regarding the experience of transgender and gender nonconforming people with fertility preservation. our aim is to describe desires, attitudes and knowledge of transgender and gender nonconforming people regarding fertility preservation wishes and reproductive needs.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * follow-up in the department of endocrinology, diabetology and nutrition of the university hospital of nancy * gender dysphoria according to the icd 11 * voluntary, informed consent to participate in research * compulsory affiliation to the social security system exclusion criteria: -refusal or incapacity to be involved in the study
a safety and efficacy study of cnto1275 in patients with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the purpose of the study is to evaluate the effectiveness and safety of cnto 1275 in patients with multiple sclerosis

multiple sclerosis (ms) is a life-long disease that usually starts in young adults. in ms, inflammation and damage to nerve cells occur in the brain and spinal cord. symptoms of ms are quite variable and may range from being mild to severe and from short to long lasting. people with ms may have a wide variety of symptoms ranging from mild to disabling. some of thesymptoms of ms include visual disturbances such as double vision, weakness in arms or legs,difficulty with coordination, fatigue, changes in sensations such as numbness and tingling, or difficulties with concentration or memory.the drug being tested in this research study is an antibody called cnto 1275. antibodies are natural substances made by the body that stick to and react with other substances in the body that may cause diseases. the body makes antibodies mainly to fight infections. cnto 1275 is an antibody that has been manufactured in the laboratory. in the test tube, cnto 1275 sticks to and blocks the activity of a naturally occurring substance in the body called interleukin 12 (il-12).higher than normal levels of il-12 have been found in people who have ms. cnto 1275 has been tested in animals with a condition similar to ms. in those animals, il-12 was over-produced.animals treated with cnto 1275 showed decreased symptoms of the condition.the purpose of this study is to better understand the safety and effectiveness of cnto 1275 in people who have relapsing-remitting ms patients will receive subcutaneous injections of 30, 100, 200 mg of cnto 1275 or placebo at weeks 0, 1, 2, 3, 7, 11, 15, and 19 or 100 mgs at weeks 0,1,2,3,11 and 19 and placebo at wks 7 and 15.

Eligibility criteria:
inclusion criteria: * have a definite diagnosis of relapsing remitting multiple sclerosis * have a history of at least 1 of the following:a. a minimum of 2 relapses of ms within the previous 2 years but not within the 1-month period prior to screening. b. a relapse of ms within the previous 6 months but not within the 1-monthperiod prior to screening exclusion criteria: * have a cns disease (eg, cns lymphoma, systemic lupus erythematous) * have significant bulbar involvement of ms or other neurologic deficits * have a decubitus ulcer * have received immunomodulatory therapies within 3 months of screening

Keywords: multiple sclerosis
mouth care regimes during radiotherapy

Conditions: Head and Neck Neoplasms

Summary: the purpose of this study is to assess whether biotene oral care products have a benefit in the treatment of xerostomia and mucositis when compared with conventional bicarbonate mouth care regimes.

grade iii and iv mucositis occurs in 30-60% of patients undergoing head and neck irradiation. where mucositis is severe a patient's ability to swallow may become significantly compromised and nutritional requirements may not be met. xerostomia is often an early side effect of treatment. as salivary tissue is very sensitive to radiation there is often a change in saliva early in the treatment. new products on the market have claimed to alleviate the symptoms of dry mouth and to help the body's natural defenses reduce the harmful oral bacteria. these products contain the important salivary enzymes lactoperoxidase, lysozyme, lactoferrin and glucose oxidase. biotene products therefore have the potential to reduce microbial populations which result in radiation caries and periodontal disease and in addition provide relief from the discomfort of xerostomia. despite the knowledge surrounding xerostomia in the head and neck irradiation population, its treatment has not been well documented and the question of patient comfort is not well addressed. comparisons: this study aims to compare the different mouth care regimes and determine the most effective treatment alternatives during radiotherapy. patients will be randomised to either biotene or bicarbonate-based mouth care regimes. patients will be stratified according to whether they are receiving radiotherapy alone or chemo irradiation to ensure equal distribution across the different mouth care regimes.

Eligibility criteria:
inclusion criteria: * are undergoing oral or pharyngeal irradiation with a cumulative dose \> 35gy with at least 1/2 of the salivary tissue contained within the field of treatment. * may or may not have undergone surgery. * are available for follow-up questionnaires. * are english speaking or have an easily accessible interpreter. exclusion criteria: * no co-morbidities which may result in dry mouth, for example sjögren syndrome.

Keywords: radiotherapy mucositis xerostomia
effect of mulligan mobilization in chronic non-spesific low back pain

Conditions: Chronic Pain

Summary: fifty five participants diagnosed with cnslbp, will randomized into three groups. group i (18 subjects) will receive 15 sessions of conventional physiotherapy program (cpp) 5 times per week, group ii (19 subjects) will receive 9 sessions of snags, and group iii will receive cpp plus snags. outcome measures are pain, rom, spinal mobility, fear avoidance behaviour and function. measurements will record before, after and 6 month after the end of the treatment.

inclussion criterias are; low back pain for at least 3 months, intensity of pain ranges from 3 to 6 according to vas. exclussion criterias are; undergoing surgical operation in the lumbar region or having a surgical indication, having an exercise therapy and / or physical therapy in the last 1 year, a history of trauma involving lumbar region and systemic and inflammatory disease targeting this region, participants using corticosteroids for a long time and being pregnant.acording to our criterias 55 participants diagnosed with cnslbp will randomised into three groups. group 1 will receive conventional physiotherapy programme consisting of hot pack, us and tens applications. group ii aill receive lumbar snags consisting of lumbar extension snags in prone, snags in lion position and lumbar flexion snags in sitting, techniques. group iii will receive 9 sessions of snags, and group iii will receive cpp plus snags.outcome measures are pain, rom, spinal mobility, fear avoidance behaviour and function. measurements will record before, after and 6 month after the end of the treatment. all treatment groups were treated with the same researcher. all assessments were made by another blind researcher three times at before, after and 6 month after treatment.

Eligibility criteria:
inclusion criteria: * low back pain for at least 3 months * intensity of pain ranges from 3 to 6 according to vas exclusion criteria: * undergoing surgical operation in the lumbar region or having a surgical indication having an exercise therapy and / or physical therapy in the last 1 year * a history of trauma involving lumbar region and systemic and inflammatory disease targeting this region * corticosteroids consumption for a long time * being pregnant.

Keywords: lumbal snags, efficiency
effectiveness of a cognitive-behavioral program of coping with psychological stress in people with retinitis pigmentosa

Conditions: Vision Disorders; Stress, Psychological; Psychopathy; Self Efficacy

Summary: the aim of this study is to evaluate the efficacy of cognitive - behavioral therapy for the control of psychopathological stress and the disease of people with retinitis pigmentosa (rp).

this randomized controlled trial aims to evaluate the efficacy of cognitive - behavioral therapy for the control of psychopathological stress and the disease of people with retinitis pigmentosa (rp) on aspects such as vulnerability to stress, perceived stress, psychopathological state, general self-efficacy, resilience, satisfaction with social support and visual field. this study has two groups: 1) cognitive - behavioral therapy group, and 2) standard intervention or control group. the two interventions will be conducted for 3 months (with a total of 12 sessions), one session per week, with a duration of 90 minutes per session.

Eligibility criteria:
inclusion criteria: * diagnosed with retinitis pigmentosa (legally blind rp patients). * meet the membership criteria of the spanish national association of once. * having a reduction of the visual field of at least 10 degrees in both eyes * having an age between 18 and 65 years. exclusion criteria: * no visual remainders (advanced retinosis). * no studies. * cognitive impairment, determined by the spanish mini-mental state examination - mmse test. * mobility problems * high risk of falls associated with retinosis, measured by the morse scale, with a score over 50 points.

Keywords: vision disorders; stress, psychological
bioequivalence between two oral nicotine sublingual tablets, 2 mg and 4 mg

Conditions: Tobacco Dependence

Summary: the purpose of this study is to assess the bioequivalence between two oral nicotine sublingual tablets, 2 mg and 4 mg.

the study is a single-dose, randomized, 2 x two-way cross-over study. the investigational products will be given as single doses at separate visits. periods without nicotine replacement therapy (nrt), lasting for at least 36 hours, will separate treatment visits. blood will be sampled at each treatment visit for pharmacokinetic analyses pre-dose, and at 5, 10, 15, 20, 30, and 45 minutes, as well as 1, 1.25, 1.5, 2, 3, 4, 6, 8, and 10 hours after start of product administration. the time until complete product dissolution will be recorded. subjects will also be monitored to capture any adverse events that may occur. the trial is open in the sense that subjects and study personnel will be aware of what product is administered at a given visit. however, the treatment labels will not be known by the people performing bioanalysis or analyzing pharmacokinetic data.

Eligibility criteria:
inclusion criteria: * healthy subjects, smoking at least 10 cigarettes daily during at least one year preceding inclusion and body mass index (bmi) between 17.5 and 30.0 kg/m2. * female participants of child-bearing potential are required to use a medically acceptable means of birth control. * a personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study. exclusion criteria: * pregnancy, lactation or intended pregnancy. * treatment with an investigational product or donation or loss of blood within 3 months preceding the first dose of study medication.

Keywords: smoking cessation nicotine pharmacokinetics
study of a flu vaccine in children

Conditions: Influenza

Summary: this study tests the safety and effectiveness of a flu vaccine in school children. school children are usually the first members of a community to come down with the flu, and they often give the flu to their younger siblings, parents, and grandparents. it is hoped that giving school children a flu vaccine can help prevent the spread of the flu to other members of the community.

this is a phase iii trial (an advanced study with a large number of patients). your child will receive a single dose of flu vaccine, which is given by a nasal spray.

Eligibility criteria:
inclusion criteria: your child may be eligible for this study if he/she: * is between the ages of 18 months and 18 years, with consent of parent or guardian. * is a resident of the temple-belton, texas area. exclusion criteria: your child will not be eligible for this study if he/she: * has had a fever within 3 days before vaccination. * has symptoms of a weakened immune system. * has had a wheezing episode within the past 2 weeks. * has moderate to severe asthma. * is allergic to eggs. * needs to take aspirin on a regular basis. * has received another vaccine or study drug in the past month.
bpf genetics of ild study

Conditions: Lung; Disease, Interstitial, With Fibrosis; Alveolitis, Extrinsic Allergic; Bird Fancier's Lung; Idiopathic Interstitial Pneumonias; Lung Diseases, Interstitial; Idiopathic Pulmonary Fibrosis

Summary: the investigators aim to examine the genetic determinants of interstitial lung disease in a cohort of subjects with regular exposure to pigeons, a known cause of one form of interstitial lung disease known as hypersensitivity pneumonitis. in addition we will examine immunological causes for hypersensitivity pneumonitis in this group. we anticipate our work will provide insights of use to clinicians and patients with hypersensitivity pneumonitis and other interstitial lung diseases.

the investigators aim to recruit participants with regular racing pigeon exposure at national (uk) and regional pigeon fancier meetings. consenting subjects will complete questionnaires, provide blood samples for genetic analysis and immunological testing and undertake lung function measurements. subjects will be observed, and encouraged to report referral to specialist respiratory services, and following this information will be sought on diagnosis (including supporting evidence). where interstitial lung disease is detected this will be linked to subsequent unbiased analysis to detect potential predisposing genetic associations.

Eligibility criteria:
inclusion criteria: * regular exposure to racing pigeons exclusion criteria: * unwilling to participate

Keywords: interstitial lung disease (ild) hypersensitivity pneumonitis idiopathic pulmonary fibrosis (ipf) extrinsic allergic alveolitis (eaa) bird fancier's lung genetics
case management study for postpartum depression and intimate partner violence

Conditions: Postpartum Depression; Intimate Partner Violence

Summary: the objective of the study was to assess the prevalence, timing, and co-occurrence of positive screens for maternal postpartum depression (ppd) and intimate partner violence (ipv) for women bringing their young infants for pediatric primary care and examine relationships between ppd, ipv and children's healthcare utilization from birth to 2 years.

post-partum depression (ppd) and intimate partner violence (ipv) negatively affect the health and well-being of millions of women each year. in turn, ppd and ipv frequently compromise women's ability to form a strong mother-infant bond, which potentially impacts their children's health and well-being. limited information exists regarding the prevalence of ppd, ipv, and the co-occurrence of the two. similarly, empirically tested interventions designed to improve outcomes for these women and their infants are lacking. the objective of the research was to assess the prevalence, timing, and co-occurrence of positive screens for maternal postpartum depression and intimate partner violence and examine their relationships with children's healthcare utilization from birth to 2 years. as per routine protocol in the harriet lane clinic (hlc), all mothers bringing their infants for a well baby visit (birth to 6 month visit) are screened for ppd and ipv using a brief, self-administered paper-based questionnaire at the start of the visit. appropriate resource and referral materials will be provided by a family support counselor (fsc) in the clinic. between february and march 2008, mothers bringing newborn, 2-, 4-, or 6-month-old children to an urban primary care clinic were screened for postpartum depression and intimate partner violence. a retrospective chart review abstracted demographic data, maternal responses on the postpartum depression/intimate partner violence screen at the initial and subsequent visits, and, from the child's birth to second birthday, adherence with well-child care and use of pediatric acute care and emergency department visits. descriptive, bivariate, and multivariate analyses were conducted.

Eligibility criteria:
inclusion criteria: * english-speaking mothers of infants presenting for their newborn, two, four or six month visits to their primary care provider in the harriet lane clinic exclusion criteria: * none

Keywords: postpartum depression intimate partner violence
determination of a proper needle entry point; effects of skin compression with an indicator on radiation exposure time of fluoroscopically guided transforaminal epidural block in obese patients

Conditions: Low Back Pain Due to Spinal Nerve Compression

Summary: to evaluate the effects of skin compression with an indicator at the needle entry point on radiation exposure time of fluoroscopically guided transforaminal epidural block in obese patients


Eligibility criteria:
inclusion criteria: * adult patients with ≥ 25 kg/m2 bmi who were scheduled for the transforaminal epidural injection exclusion criteria: * local anesthetic allergy, coagulopathy
efficacy and tolerance of 4 weeks of tedizolid in prosthetic joint infections treated with implant removal

Conditions: Prostheses Infection

Summary: to evaluate the efficacy of 4 weeks of 200 mg/24h of tedizolid for prosthetic join infections caused by tedizolid susceptible microorganisms treated with implant removal in one or two stages at 6 months of followup after stopping tedizolid treatment.

to evaluate the efficacy of 4 weeks of 200 mg/24h of tedizolid for prosthetic join infections caused by tedizolid susceptible microorganisms treated with implant removal in one or two stages at 6 months of followup after stopping tedizolid treatment. secondary objectives: evaluate the efficacy of tedizolid at 12 months of follow-up; evaluate the rate of gastrointestinal adverse events with tedizolid; determine the rate of haematological abnormalities during tedizolid treatment and; in case of two-stage exchange, the rate of positive cultures during reimplantation.

Eligibility criteria:
inclusion criteria: 1. male or female older than 18 years who accept and sign the informed consent. 2. infection signs onset more than 3 months after index arthroplasty. 3. diagnostic of chronic (≥3 weeks of clinical symptoms) hip or knee prosthetic joint infection according to msis criteria \*(parvizi j, gherke t. definition of peri-prosthetic joint infection. j arthroplasty 2014; 29: 1331) 4. infection due to a tedizolid susceptible microorganism. 5. surgical approach: one or two - stage exchange of all implant components. 6. willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. exclusion criteria: 1. patients with a prosthetic joint infection with negative cultures. 2. patients who undergo debridement without removing the prosthesis or only partially removed 3. ≥15 days of other antibiotic treatment before starting tedizolid 4. life expeancy ≤ 1 year. 5. previous enrollment in this protocol. 6. hypersensitivity to tedizolid or any formulation excipients. 7. concurrent use of another investigational medication within 30 days of study entry. 8. women who are pregnant or breast-feeding
pilot study of riluzole for drug-refractory irritability in autism spectrum disorders

Conditions: Autism Spectrum Disorders

Summary: determine if riluzole shows evidence of efficacy, safety, and tolerability targeting drug-refractory irritability (dri) in persons with autism spectrum disorders (asd).

a randomized, double blind, placebo-controlled, 12-week cross-over study (5-week treatment periods with 2-week washout) of adjunctive riluzole in 12 persons with asd and dri between the ages of 12 and 25 years.

Eligibility criteria:
inclusion criteria: * age ≥ 12 and \< 26 years. * weight greater than 50 kg. * diagnosis of asd * drug-refractory irritability, as defined as screening abc irritability subscale (abc-i) score of ≥18 and 1) failure of clinically adequate treatment trials of both aripiprazole and risperidone or 2) failure of at least three previous clinically adequate drug trials targeting irritability (one trial must include aripiprazole or risperidone), as confirmed by caregiver reports and medical record review when available. * stable dosing of all concomitant psychotropic medications (including those targeting irritability) for four weeks prior to screening visit and during the study. * presence of parent/guardian willing to serve as informant for behavioral outcome measures and shipping control sample for extracellular signal-related kinase biomarker (erk) assay. exclusion criteria: * current use of more than two concomitant psychotropic drugs targeting irritability. * current use of valproic acid. * current use of drugs with known interaction with riluzole * current use of drugs with concomitant glutamatergic or glutamatergic- modulating action medications. * for female subjects of child bearing potential, a positive serum pregnancy test. * history of pancreatitis. * hemoglobin less than or equal to 8.0 gm/dl. * neutropenia with absolute neutrophil count less than or equal to 1.0 k/mcl. * problems with kidney functioning, as assessed by lab work * any major chronic medical or chronic respiratory illness considered to be uncontrolled by the principal investigator.